Cargando...
CRISPR/Cas9 gene editing for curing sickle cell disease
Sickle cell disease (SCD) is the most common monogenic blood disorder marked by severe pain, end-organ damage, and early mortality. Treatment options for SCD remain very limited. There are only four FDA approved drugs to reduce acute complications. The only curative therapy for SCD is hematopoietic...
Guardado en:
| Publicado en: | Transfus Apher Sci |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8049447/ https://ncbi.nlm.nih.gov/pubmed/33455878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.transci.2021.103060 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|